EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients
- 31 March 2007
- journal article
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 173 (2) , 107-113
- https://doi.org/10.1016/j.cancergencyto.2006.10.007
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- EGFR point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplificationCancer Science, 2006
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- EGFR and erbB2 mutation status in Japanese lung cancer patientsInternational Journal of Cancer, 2005
- Absence of theERBB2 kinase domain mutation in lung adenocarcinomas in Korean patientsInternational Journal of Cancer, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI Journal of the National Cancer Institute, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- STAT proteins: From normal control of cellular events to tumorigenesisJournal of Cellular Physiology, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancerMolecular Carcinogenesis, 1992